New therapeutic weapons in stage IV melanoma;Nouvelles armes thérapeutiques contre le mélanome de stade IV

Revue Medicale Suisse

Volumn 9, Issue 387, 2013, Pages 1095-1098

  Tzika, E ^a   Moura, B ^a   Romano, E ^a   Michielin, O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL (TOPIC); HUMAN; MELANOMA; PATIENT CARE; REVIEW;

HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM STAGING;

EID: 84878914698     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. * Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
2. ** Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. * Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
4. * Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
5. Taube JM, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127-37.
6. ** Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
7. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80:561-7.
8. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-85. (Pubitemid 39486539)
9. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005;6:827-37. (Pubitemid 41568732)
10. * Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011;12:913-22.
11. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183-9. (Pubitemid 351317406)
12. ** Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
13. Straussman R, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
14. Paraiso KHT, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102:1724-30.
15. ** Flaherty KT, et al. Improved survival with mek inhibition in braf-mutated melanoma. N Engl J Med 2012;367:107-14.
16. ** Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.